Compare IOT & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IOT | JAZZ |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.5B | 15.6B |
| IPO Year | 2021 | 2007 |
| Metric | IOT | JAZZ |
|---|---|---|
| Price | $32.99 | $254.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | $45.42 | ★ $217.57 |
| AVG Volume (30 Days) | ★ 5.3M | 659.5K |
| Earning Date | 06-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.86 | N/A |
| EPS | 0.08 | ★ 4.43 |
| Revenue | $1,618,635,000.00 | ★ $1,618,693,000.00 |
| Revenue This Year | $23.00 | $6.22 |
| Revenue Next Year | $19.69 | $7.68 |
| P/E Ratio | $393.63 | ★ $57.53 |
| Revenue Growth | ★ 29.57 | N/A |
| 52 Week Low | $23.38 | $105.00 |
| 52 Week High | $47.47 | $255.20 |
| Indicator | IOT | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 44.29 | 62.37 |
| Support Level | $28.31 | $222.49 |
| Resistance Level | $35.70 | N/A |
| Average True Range (ATR) | 2.27 | 7.52 |
| MACD | -0.60 | 0.84 |
| Stochastic Oscillator | 19.41 | 86.30 |
Samsara Inc provides an end-to-end solution for operations. The company's Connected Operations Platform consolidates data from its IoT devices and a growing ecosystem of connected assets and third-party systems, and makes it easy for organizations to access, analyze, and act on data insights using its cloud dashboard, custom alerts and reports, mobile apps, and workflows. The company derives almost all of its revenue from subscription services. Geographically, it derives a majority of its revenue from the United States. The company's customers range from small and medium-sized businesses to state and local governments.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.